CervoMed Strengthens Board with Appointment of Life Sciences Business Strategy Leader David Quigley
CervoMed Inc. (CRVO)
Company Research
Source: GlobeNewswire
Mr. Quigley most recently led McKinsey & Company’s Private Capital practice and previously led various Life Sciences practices at the firm Appointment adds deep business strategy, transactional, and commercial expertise as CervoMed prepares for Phase 3 and commercialization planning BOSTON, Oct. 28, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO) (CervoMed or the Company), a clinical-stage biotechnology company developing treatments for age-related brain disorders, today announced the appointment of David Quigley to its Board of Directors (Board). Mr. Quigley is a seasoned executive and former Senior Partner at McKinsey & Company, where he led the firm’s Life Sciences and Private Equity practices. His appointment comes as CervoMed prepares for key milestones, including U.S. Food and Drug Administration (FDA) feedback on the design of its planned Phase 3 trial in patients with dementia with Lewy bodies (DLB), expected during the fourth quarter of 2025. “It is a pleasure to w
Show less
Read more
Impact Snapshot
Event Time:
CRVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRVO alerts
High impacting CervoMed Inc. news events
Weekly update
A roundup of the hottest topics
CRVO
News
- CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy BodiesGlobeNewswire
- CervoMed (NASDAQ:CRVO) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $31.00 price target on the stock.MarketBeat
- CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB)GlobeNewswire
- CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) ConferenceGlobeNewswire
- CervoMed (NASDAQ:CRVO) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $31.00 price target on the stock.MarketBeat
CRVO
Earnings
- 11/7/25 - Miss
CRVO
Sec Filings
- 12/5/25 - Form 4
- 12/5/25 - Form 3
- 12/5/25 - Form 8-K
- CRVO's page on the SEC website